This study presents evidence in support of the continued development of previously established inhibitory therapeutics that target select protein kinases, such as epidermal growth factor receptor (EGFR) [25], ephrin receptor A2 (EPHA2) [29], and SRC proto-oncogene kinase (SRC) [27], and our experimental results identify new PDAC targets, such as B lymphoid kinase (BLK), lymphocyte cell-specific kinase (LCK), and ABL proto-oncogene 2 kinase (ABL2), which may play a critical role in cancer cell biochemistry or desmoplastic inflammatory cell behavior. Here, BLK is linked to cancer.